211 related articles for article (PubMed ID: 10561339)
1. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Day R; Ganz PA; Costantino JP; Cronin WM; Wickerham DL; Fisher B
J Clin Oncol; 1999 Sep; 17(9):2659-69. PubMed ID: 10561339
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
[TBL] [Abstract][Full Text] [Related]
3. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial.
Ganz PA; Day R; Ware JE; Redmond C; Fisher B
J Natl Cancer Inst; 1995 Sep; 87(18):1372-82. PubMed ID: 7658498
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project.
Day R;
Ann N Y Acad Sci; 2001 Dec; 949():143-50. PubMed ID: 11795346
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
6. Life after breast cancer: understanding women's health-related quality of life and sexual functioning.
Ganz PA; Rowland JH; Desmond K; Meyerowitz BE; Wyatt GE
J Clin Oncol; 1998 Feb; 16(2):501-14. PubMed ID: 9469334
[TBL] [Abstract][Full Text] [Related]
7. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
Powles T; Eeles R; Ashley S; Easton D; Chang J; Dowsett M; Tidy A; Viggers J; Davey J
Lancet; 1998 Jul; 352(9122):98-101. PubMed ID: 9672274
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.
Fallowfield L; Fleissig A; Edwards R; West A; Powles TJ; Howell A; Cuzick J
J Clin Oncol; 2001 Apr; 19(7):1885-92. PubMed ID: 11283119
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
[TBL] [Abstract][Full Text] [Related]
10. Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.
Land SR; Walcott FL; Liu Q; Wickerham DL; Costantino JP; Ganz PA
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26615179
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study.
Day R; Ganz PA; Costantino JP
J Natl Cancer Inst; 2001 Nov; 93(21):1615-23. PubMed ID: 11698565
[TBL] [Abstract][Full Text] [Related]
12. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women.
Cella D; Land SR; Chang CH; Day R; Costantino JP; Wolmark N; Ganz PA
Breast Cancer Res Treat; 2008 Jun; 109(3):515-26. PubMed ID: 17851765
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
14. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Whelan TJ; Goss PE; Ingle JN; Pater JL; Tu D; Pritchard K; Liu S; Shepherd LE; Palmer M; Robert NJ; Martino S; Muss HB
J Clin Oncol; 2005 Oct; 23(28):6931-40. PubMed ID: 16157934
[TBL] [Abstract][Full Text] [Related]
15. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.
Veronesi U; Maisonneuve P; Costa A; Sacchini V; Maltoni C; Robertson C; Rotmensz N; Boyle P
Lancet; 1998 Jul; 352(9122):93-7. PubMed ID: 9672273
[TBL] [Abstract][Full Text] [Related]
16. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer: risk, prevention, & tamoxifen.
Machia J
Am J Nurs; 2001 Apr; 101(4):26-35; quiz 36. PubMed ID: 11301680
[No Abstract] [Full Text] [Related]
19. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors.
Ganz PA; Rowland JH; Meyerowitz BE; Desmond KA
Recent Results Cancer Res; 1998; 152():396-411. PubMed ID: 9928575
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment.
Veronesi A; Pizzichetta MA; Ferlante MA; Zottar M; Magri MD; Crivellari D; Foladore S
Tumori; 1998; 84(3):372-5. PubMed ID: 9678620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
